Immediate LDL-C reduction after an acute coronary syndrome (ACS) has been linked, as aforementioned, with significant benefits in mortality and adverse outcomes in both statin and PCSK9 studies in cohorts evaluating immediate initiation of LDL-C lowering treatment. Here, PCSK9 is linked to acute coronary syndrome.